Read More Pharma Industry News Is ATEV the first scalable alternative to autologous fistulas in hemodialysis access Can Humacyte, Inc. turn ATEV into a viable dialysis access alternative? Dive into Phase 3 signals, risks, and market impact shaping its future. bySoujanya RaviApril 30, 2026